We observed that the limited cytotoxicity of adoptive NK cells against pancreatic cancer organoids could be enhanced by including the ADCC-inducing antibodies avelumab and trastuzumab, targeting PD-L1 and HER2, respectively. This evidence concerns the gene ERBB2 and pancreatic neoplasm.